Canadian authors compared 694 incident cases of ovarian cancer with the most commonly reported BRCA1 or BRCA2 mutations identified in 60 patients (between them the same as in our current study: 185delAG, 4075delGT, 6174delT) to 4378 relatives of cases who did not carry a mutation and estimated that the relative risk of GC in carriers of those mutations or relatives of cases was comparable to the previously cited author (RR = 6.2; 95 % CI 2–19) [10]. This evidence concerns the gene BRCA2 and ovarian cancer.